UnitedHealth Group (NYSE:UNH) today reported fourth quarter and full
year 2014 results, highlighted by Optum’s exceptional revenue growth,
margin expansion and earnings advances and broad-based strength in
UnitedHealthcare’s public and senior sector benefits business.
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called Accurins TM , today presented positive results from its
ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC),
demonstrating it has met the primary objective in the once every three
weeks (Q3W) arm as measured by overall response rate (ORR). The data
demonstrate that BIND-014 is well-tolerated with clinically meaningful
anti-tumor activity at a lower dose than conventional docetaxel in
patients with advanced or metastatic NSCLC.
Sign-up for BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium investment picks
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.